GSK acquires exclusive marketing rights for new topical patch from Labtec GmbH

Download PDF Copy

Jun 21 2010

In a recently finalized license agreement, the Consumer Healthcare division of GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec GmbH, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer.

“In GlaxoSmithKline we have found an outstanding development and marketing partner for our innovative patch technology”

The product is based on Labtec's proprietary LabiPatch platform technology. It is especially suitable for easy, convenient application of patches on the delicate surface of the lip. Encompassing patches with and without active ingredients, the LabiPatch technology is designed to promote the healing process by maintaining a moist and optimal healing environment.

"In GlaxoSmithKline we have found an outstanding development and marketing partner for our innovative patch technology," says Ingo Lehrke, Managing Director of Labtec. "We are confident that this partnership will deliver improved therapy options for a multitude of patients suffering from cold sores."

Source:

Labtec GmbH

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

AI rollout in NHS hospitals faces major challenges

Common cold may offer temporary protection against SARS-CoV-2 infection

UCSF research maps over 600 conditions linked to endometriosis

Better technology access reduces healthcare gaps for African Americans

Duke-NUS sharpens focus on population health and technology-enabled research

Does soup really work when you’re down with cold or flu?

AI transforms healthcare for faster, smarter care in emergency crises

Scaling organ‑chip technology for human‑relevant drug discovery

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.